|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.1600 - 0.1600|
|52 Week Range||0.1300 - 3.4700|
|Beta (3Y Monthly)||3.66|
|PE Ratio (TTM)||0.47|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NEW YORK, NY / ACCESSWIRE / July 27, 2018 / Biostar shares saw a rebound on Thursday, closing the day up over 27% after falling on Wednesday when Wall Street learned the company had received a delisting ...
XIANYANG, CHINA / ACCESSWIRE / July 25, 2018 / Biostar Pharmaceuticals, Inc. (BSPM) (''the Company''), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that on July 19, 2018 it received a notification letter from Nasdaq Listing Qualifications (''Nasdaq'') advising the Company that following review of the Company's plan of compliance, the Nasdaq staff determined to delist the Company's common stock from the Nasdaq Capital Market. The delisting notification stated that such delisting would be effective at the opening of business on July 30, 2018 unless the Company requests an appeal of the delisting determination. As previously disclosed, the Company was cited for failures to comply with this Listing Rule because it had not filed its Form 10-K for the year ended December 31, 2017 and its Form 10-Q for the period ended March 31, 2018.